Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GPCR
STRUCTURE THERAPEUTICS INC.
NASDAQ
$47.34
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$2.72 B
52w High$94.90
52w Low$20.04
Dividend Yield—
Frequency—
P/E-30.15
Volume253.40K
Shares Out.57.57M

COMPANY

LEADERSHIP

Raymond C. Stevens
CHIEF EXECUTIVE
Raymond C. Stevens

COMPENSATION 2026

Salary$672,094
Stock Awards$2,387,996
Incentive Plan Pay$508,871
All Other Comp.$14,000
Total$8,429,887

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 3, 2023
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
281

PRICE TARGET

Target High$145.00
Target Low$70.00
Target Median$111.00
Target Consensus$108.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$45.45M
NOV
5
THU

PRICE

$47.34 ▲ UP 0.00% (+$0.00)
$46.80$47.20$47.60$48.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM47.34

About Structure Therapeutics Inc.

https://structuretx.com ↗

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral therapeutics, including GSBR-1290 for diabetes and obesity, and other GPCR-targeted drugs for pulmonary and cardiovascular diseases.

INDUSTRY

Biotechnology

A PRODUCT STRUCTURE THERAPEUTICS INC. IS KNOWN FOR

GSBR-1290 (Aleniglipron)
GSBR-1290 (Aleniglipron)

GSBR-1290 (Aleniglipron) is an oral small molecule GLP-1 receptor agonist in Phase 2 trials for obesity and type 2 diabetes, offering a convenient alternative to injectables and advancing Structure Therapeutics' focus on accessible metabolic disea...

COMPETITORS

COMPETITOR
AMGN COMPARE
LLY COMPARE
NVO COMPARE
PFE COMPARE
VKTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
30
LISTED HERE
15
RANKED BY POSITION SIZE
IBB
0.19% · 434.5K
SBIO
1.87% · 98.0K
FDG
0.81% · 61.8K
FSMO
0.15% · 49.3K
OZEM
2.61% · 34.5K
EWX
0.23% · 33.6K
LRNZ
3.99% · 33.1K
WBIO.L
1.66% · 14.7K
APIE
0.04% · 9.8K
BBC
0.68% · 7.3K
IBBQ
0.24% · 5.0K
BIB
0.12% · 2.8K
MMSC
0.24% · 2.6K
GDOC
0.44% · 1.8K
TNXT
0.09% · 345

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.24%
HOLDERS
263
TOP 12 OF 263 · RANKED BY POSITION SIZE
Fmr LLC
8.7M sh · $605.94M
Wellington Management Group Llp
7.3M sh · $349.95M
Avoro Capital Advisors LLC
6.6M sh · $315.98M
Janus Henderson Group Plc
5.1M sh · $354.01M
Deep Track Capital, LP
4.3M sh · $206.29M
Bvf Inc/Il
3.5M sh · $241.97M
Morgan Stanley
2.3M sh · $111.12M
Price T Rowe Associates Inc /Md/
2.0M sh · $96.43M
Principal Financial Group Inc
1.8M sh · $84.53M
Driehaus Capital Management LLC
1.6M sh · $114.23M
Baker Bros. Advisors LP
1.6M sh · $43.57M
Casdin Capital, LLC
1.6M sh · $43.54M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

TRADES BY CONGRESS

SENATE TRADES
Thomas R. Carper
Thomas R. Carper
Sale (Full)
2023-10-04
 Thomas Richard Carper
Thomas Richard Carper
Sale (Full)
2023-10-04

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lin Xichen
Purchase · 17.8K shares
2026-09-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lin Xichen
Sale · 17.8K shares
2026-09-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lin Xichen
Purchase · 5.9K shares
2026-09-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lin Xichen
Sale · 1.3K shares
2026-09-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 2
MARKET OUTPERFORM 1
9 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Citigroup BUY HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Guggenheim BUY Morgan Stanley OVERWEIGHT Jefferies BUY Stifel BUY

SECTORS PEERS

PEERPRICE
LQDA$68.41COMPARE
EWTX$42.75COMPARE
ABCL$11.41COMPARE
QURE$44.20COMPARE
CLDX$39.54COMPARE
VRDN$22.84COMPARE
NUVB$6.84COMPARE
OCUL$10.75COMPARE